ROLE OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN THE DYSLIPIDEMIA AND NONALCOHOLIC FATTY LIVER DISEASE PATHOGENESIS

Authors:

Abstract:

Nonalcoholic fatty liver disease is one of the most prevalent chronic liver conditions, often associated with dyslipidemia and metabolic syndrome. Small intestinal bacterial overgrowth is considered a key mechanism potentially contributing to the development of non-alcoholic fatty liver disease and dyslipidemia by affecting metabolic balance, lipid metabolism, and systemic inflammation. This study examined 342 patients with dyslipidemia, assessing the prevalence of small intestinal bacterial overgrowth and its impact on lipid metabolism parameters and inflammatory markers. A significantly higher frequency of small intestinal bacterial overgrowth was found in patients with lipid metabolism disorders (53.4 %) compared to the control group (36 %, p≤0.05) and among those with non-alcoholic fatty liver disease (52 %). Correlation analysis confirmed the association of small intestinal bacterial overgrowth with elevated triglyceride levels, alkaline phosphatase, and insulin resistance index. The findings underscore the significance of small intestinal bacterial overgrowth in the pathogenesis of non-alcoholic fatty liver disease and dyslipidemia, highlighting new opportunities for the diagnosis and treatment of these conditions.

Keywords:

nonalcoholic fatty liver disease small intestinal bacterial overgrowth dyslipidemia steatosis steatohepatitis

References:

1. Solomentseva TA. Novi kryteriyi metabolichno-asotsiyovanoyi zhyrovoyi khvoroby pechinky: perevaha chy pytannia? Ohliad. Suchasna hastroenterolohiya. 2023;4:84–90. [in Ukrainian].
2. Banaszak M, Górna I, Woźniak D, Przysławski J, Drzymała-Czyż S. Association between Gut Dysbiosis and the Occurrence of SIBO, LIBO, SIFO and IMO. Microorganisms. 2023 Feb 24;11(3):573. doi: 10.3390/microorganisms11030573.
3. Chen J, Vitetta L. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. Int J Mol Sci. 2020 Jul 23;21(15):5214. doi: 10.3390/ijms21155214.
4. Gkolfakis P, Tziatzios G, Leite G, Papanikolaou IS, Xirouchakis E, Panayiotides IG, et al. Prevalence of Small Intestinal Bacterial Overgrowth Syndrome in Patients with Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis: A Cross-Sectional Study. Microorganisms. 2023 Mar 10;11(3):723. doi: 10.3390/microorganisms11030723.
5. Gudan A, Jamioł-Milc D, Hawryłkowicz V, Skonieczna-Żydecka K, Stachowska E. The Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Non-Alcoholic Liver Diseases: NAFLD, NASH, Fibrosis, Cirrhosis-A Systematic Review, Meta-Analysis and Meta-Regression. Nutrients. 2022 Dec 9;14(24):5261. doi: 10.3390/nu14245261.
6. Gudan A, Kozłowska-Petriczko K, Wunsch E, Bodnarczuk T, Stachowska E. Small Intestinal Bacterial Overgrowth and Non-Alcoholic Fatty Liver Disease: What Do We Know in 2023? Nutrients. 2023 Mar 8;15(6):1323. doi: 10.3390/nu15061323.
7. Kvit KB, Kharchenko NV, Kharchenko VV, Chornenka OI, Chornovus RI, Dorofeeva US, et al. The role of small intestinal bacterial overgrowth in the pathogenesis of hyperlipidemia. Wiad Lek. 2019;72(4):645-649.
8. Lau LHS, Wong SH. Microbiota, Obesity and NAFLD. Adv Exp Med Biol. 2018; 1061:111–125. doi: 10.1007/978-981-10-8684-7_9.
9. Ouyang Q, Xu Y, Ban Y, Li J, Cai Y, Wu B, et al. Probiotics and Prebiotics in Subclinical Hypothyroidism of Pregnancy with Small Intestinal Bacterial Overgrowth. Probiotics Antimicrob Proteins. 2024 Apr;16(2):579–588. doi: 10.1007/s12602-023-10068-4.
10. Quigley EMM. The Spectrum of Small Intestinal Bacterial Overgrowth (SIBO). Curr Gastroenterol Rep. 2019 Jan 15;21(1):3. doi: 10.1007/s11894-019-0671-z.
11. Ruscio M. Is SIBO A Real Condition? Altern Ther Health Med. 2019 Sep;25(5):30–38.
12. Shi H, Mao L, Wang L, Quan X, Xu X, Cheng Y, et al. Small intestinal bacterial overgrowth and orocecal transit time in patients of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1): e535-e539. doi: 10.1097/MEG.0000000000002157.
13. Sroka N, Rydzewska-Rosołowska A, Kakareko K, Rosołowski M, Głowińska I, Hryszko T. Show Me What You Have Inside-The Complex Interplay between SIBO and Multiple Medical Conditions-A Systematic Review. Nutrients. 2022 Dec 24;15(1):90. doi: 10.3390/nu15010090.
14. Zeigerer A. NAFLD – A rising metabolic disease. Mol Metab. 2021 Aug; 50:101274. doi: 10.1016/j.molmet.2021.101274.

Publication:

«World of Medicine and Biology» Vol. 20 No. 90 (2024) , с. 63-68
УДК 616.36-003.826 + 616.153.915)]-078-037

DOI:

https://doi.org/10.26724/2079-8334-2024-4-90-63-68